

Anti-cytokine autoantibodies are ubiquitous in healthy individuals

Masato Watanabe^{a,b}, Kanji Uchida^c, Kazuhide Nakagaki^d, Hiroko Kanazawa^a,
Bruce C. Trapnell^c, Yoshihiko Hoshino^e, Hiroshi Kagamu^a, Hirohisa Yoshizawa^a,
Naoto Keicho^f, Hajime Goto^b, Koh Nakata^{a,*}

^a Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata 951-8520, Japan

^b First department of Internal Medicine, School of Medicine, Kyorin University, Tokyo 181-8611, Japan

^c Division of Pulmonary Biology and Neonatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

^d Laboratory of Wildlife, College of Veterinary, Nippon Veterinary and Life Science University, Tokyo 180-8602, Japan

^e Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA

^f Department of Respiratory Diseases, International Medical Center of Japan, Tokyo 162-8655, Japan

Received 17 February 2007; revised 3 April 2007; accepted 16 April 2007

Available online 24 April 2007

Edited by Masayuki Miyasaka

Abstract Anti-cytokine autoantibodies in healthy individuals have been widely reported but the occurrence is variable and inconstant. We hypothesized that cytokine-binding *in vivo* may explain their variable and infrequent detection. Therefore, we focused on the detection of the cytokine-autoantibody complexes and found that anti-cytokine autoantibody to IL-2, IL-8, tumor necrosis factor- α , vascular endothelial growth factor and granulocyte-colony stimulating factor were present in all 15 individuals evaluated, while those to IL-3, osteopontin and macrophage-colony stimulating factor were not detected in anyone. Autoantibodies against IL-4, IL-6, IL-10, and interferon-gamma were variously detected. Thus, we discovered that anti-cytokine autoantibodies to multiple cytokines are ubiquitous in healthy individuals.

© 2007 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

Keywords: Autoantibody; Cytokine; Vascular endothelial growth factor; Immune complex; Healthy individual

1. Introduction

Anti-cytokine autoantibodies are present in a number of chronic inflammatory diseases [1,2], although a pathogenic role has not been clarified in most. In some instances, however, anti-cytokine autoantibodies are believed to be central to disease pathogenesis. For example, in some cases of Felty's syndrome, neutralizing autoantibodies against granulocyte-colony stimulating factor (G-CSF) appear to mediate neutropenia [3]. In pulmonary alveolar proteinosis, autoantibodies against granulocyte macrophage-colony stimulating factor

(GM-CSF), which eliminate GM-CSF bioactivity *in vivo*, appear to cause alveolar macrophage dysfunction, resulting in impaired clearance of pulmonary surfactant, and respiratory insufficiency [4–6].

Anti-cytokine autoantibodies have been reported to be readily detected in some commercially available pharmaceutical intravenous human immunoglobulin (IVIG) preparations [7,8]. Anti-cytokine autoantibodies have also been detected, albeit rarely, in the sera of healthy individuals. For example, 1 in 300 individuals are positive for anti-cytokine antibodies by enzyme-linked immunosorbent assay (ELISA) [8] and 1 in 60 individuals are positive by radio-immuno assay [9]. The apparent discrepancy might be explained by inclusion of individuals with highly elevated levels of serum anti-cytokine autoantibodies in the donor pool used for preparing commercial immunoglobulin. Alternatively, anti-cytokine autoantibodies may be present at low levels in the serum of most healthy individuals, but in a poorly detectable form. In the present study, we hypothesized that anti-cytokine autoantibodies are highly prevalent in healthy individuals and that formation of cytokine autoantibody complexes *in vivo* impairs their detection by commonly used immunological methods based on ligand specificity. To elucidate this, we focused on the detection of cytokine-autoantibody complex by a newly developed method. We demonstrate the ubiquitous presence of anti-cytokine autoantibody in healthy individuals.

2. Materials and methods

2.1. Study subjects

Healthy individual was defined as one who did not have apparent past history of disease including cancer, collagen disease, and infection nor current episode of minor disease like common cold, allergy, and fatigue for one month. Every participants underwent health checkup annually. Eleven sera (male; $n = 5$, 30–51 y.o., female; $n = 6$, 20–49 y.o.), the three lots of fresh frozen plasma (FFP, Nisseki), and one lot of IVIG (Venoglobulin[®]-IH, Mitsubishi Pharma Corporation) were analyzed.

2.2. Dissociation of cytokine-autoantibody complexes

Serum/plasma or IVIG was fractionated with polyethylene glycol 6000 in order to precipitate both immune complex and free IgG, and to separate from free cytokines included in supernatant. The precipitate was re-suspended in 10 mM TBS (pH 8.0) and subjected to protein A/G column. Immunoglobulin G (IgG) was eluted with 100 mM

*Corresponding author. Fax: +81 25 227 0377.

E-mail address: radical@med.niigata-u.ac.jp (K. Nakata).

Abbreviations: G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte macrophage-colony stimulating factor; IVIG, pharmaceutical intravenous human immunoglobulin; VEGF, vascular endothelial growth factor; AutoAb_{VEGF}, autoantibody against VEGF; TNF- α , tumor necrosis factor- α ; Biotin-VEGF, Biotinylated recombinant human VEGF; K_{av} , average binding affinity; OPN, osteopontin; M-CSF, macrophage-colony stimulating factor; IFN- γ , interferon-gamma; ARDS, acute respiratory distress syndrome

glycine–HCl/0.15 M NaCl (pH 2.1) or ionic strength buffer (pH 6.55). The eluate was applied onto a spin column for ultrafiltration (Microcon® Centrifugal Filter Unit, Millipore, MW 100 kDa) and centrifuged at 6000 × *g* in order to separate autoantibodies from autoantigens smaller than the 100 kDa. Recovered IgG were dialyzed against 10 mM TBS (pH 8.0). Recovered autoantigens were dialyzed against 10 mM TBS (pH 8.0) in the presence of bovine serum albumin (BSA), and concentrated with hygroscopic and high M.W. compound (PIERCE). This procedure for dissociation of cytokine–autoantibody complex was optimized by using vascular endothelial cell growth factor (VEGF)–monoclonal anti-VEGF antibody complex model as shown in [supplementary data](#).

2.3. Isolation of autoantibody against VEGF (*autoAb*_{VEGF})

*AutoAb*_{VEGF} in acidified and size-separated IVIG (pH 2.1) was isolated with affinity chromatography coupled with rhVEGF, and eluted with 10 mM glycine–HCl/0.15 M NaCl (pH 2.1).

2.4. Immunoblotting

Cytokines (100 ng) were subjected to SDS–PAGE under reducing conditions and transferred to polyvinylidene fluoride membrane. The membrane was blocked and hybridized with acidified-ultrafiltrated IgG fraction for 2 h. Bound IgG was detected with HRP–anti-human IgG (Fab')₂ and visualized with ECL plus (GE Healthcare).

2.5. ELISA

Binding specificity of isolated *autoAb*_{VEGF} was examined on ELISA plate pre-coated with cytokines, and determined by polymer–HRP–anti-human IgG. Inhibitory binding assay was carried out by incubating with recombinant human VEGF (rhVEGF) or recombinant human tumor necrosis factor- α (rhTNF- α) (final 2.4 μ g/mL) prior to ELISA. IgG concentration of *autoAb*_{VEGF} was measured by IgG assay kit (PIERCE).

The concentration of G-CSF or macrophage–colony stimulating factor (M-CSF) was also measured by ELISA kit (Biosource and R&D, respectively).

The occurrence of free anti-cytokine autoantibody in sera/plasma was determined by ELISA plate pre-coated with cytokines followed by detection with HRP–anti-human IgG(Fab')₂. When the OD value was higher than mean + 3S.D. of control level (cytokine not coated), the results were determined as positive.

2.6. Saturation binding assay

Biotinylated recombinant human VEGF (Biotin–VEGF) was made by NHS–PEO₄–Biotin (PIERCE). *AutoAb*_{VEGF} or control IgG (humanized monoclonal anti-CD 20 antibody) was incubated with Biotin–VEGF (0–26.2 nM), each solution including Biotin–VEGF–*autoAb*_{VEGF} complex was captured on ELISA plate pre-coated with anti-human IgG, and detected with AP–streptavidin, and CDP–Star® with Sapphire-II™ Enhancer (Applied Biosystems). Based on a Michaelis–Menten plot, average binding affinity (K_{av}) was determined from the concentration of free VEGF at 50% of the maximal binding.

3. Results

3.1. Occurrence of cytokine–autoantibody complexes in healthy individuals

We hypothesized that low or variable frequency in detection of the anti-cytokine autoantibodies in healthy individuals is due to the formulation of cytokine–autoantibody complex in vivo. To evaluate this, we focused on detection of the complex by a newly developed acidification–ultrafiltration procedure described in Section 2. We first evaluated the occurrence of anti-cytokine autoantibodies in commercially available IVIG preparations. Autoantibodies against VEGF, interleukin (IL)-2 and IL-8 were not detected in free IgG but were readily detected in the complex ([Fig. 1A](#)). We next evaluated the occurrence of the autoantibodies in serum/plasma from disease-free, healthy human individuals. Similar to the re-

sults with IVIG, autoantibodies against VEGF, IL-2 and IL-8 were readily detected in the complex but not in the free IgG ([Fig. 1B](#)). Then, autoantibodies directed at other cytokines were evaluated in the complex of serum/plasma of disease-free, healthy human individuals using a series of cytokine ligands for immunoblotting-based detection. Interestingly, all individuals tested had autoantibodies against multiple different cytokines ([Fig. 1C](#), [Table 1](#)). Of the 15 individuals evaluated, all had autoantibodies against IL-2, IL-8, TNF- α , VEGF and G-CSF, 14 had autoantibodies to IL-4, 11 had autoantibodies to IL-10, and only 1 had antibodies to IL-6 or to interferon-gamma (IFN- γ). In contrast, no individuals had autoantibodies to IL-3, osteopontin (OPN), or to M-CSF either with or without acidification–ultrafiltration. None of the anti-cytokine autoantibodies evaluated were detected in the free IgG of serum/plasma samples ([Table 1](#)). These results demonstrate that anti-cytokine autoantibody is ubiquitously present in the form of cytokine–autoantibody complex in human serum and IVIG.

3.2. Binding specificity of *autoAb*_{VEGF}

To establish the specificity of anti-cytokine autoantibodies for their ligand targets, we first isolated *autoAb*_{VEGF} from commercially available IVIG using the acidification–ultrafiltration step followed by VEGF–affinity chromatography. *AutoAb*_{VEGF} was highly specific for VEGF ([Fig. 2A](#)), using a cytokine capture-based ELISA as we have previously used to demonstrate the specificity of anti-cytokine antibodies [6]. Further, soluble VEGF but not TNF- α significantly inhibited the detection of the autoantibody by ELISA ([Fig. 2B](#)). To further characterize the *autoAb*_{VEGF}, using a saturation binding plot approach, we determined the K_{av} of affinity-purified antibody to be 2.9 nM ([Fig. 2C](#)). Thus, *autoAb*_{VEGF} from the serum of healthy individuals binds specifically to VEGF with moderate affinity.

3.3. Detection of bound ligand cytokines

While some cytokines (e.g., M-CSF) are readily detectable in serum, others (G-CSF) are not or are present in very low abundance. Hypothesizing that poorly detectable/low abundance serum cytokines may be present in the form of immune complexes and vice versa, we evaluated the acidified ultrafiltrate of human serum for the presence of M-CSF and G-CSF by ELISA. The level of detectable G-CSF in the serum ultrafiltrate was greatest when acidification was performed at a pH of 2.1 ([Fig. 3A](#)). Evaluation of serum from six individuals with and without acidification–ultrafiltration revealed that G-CSF in healthy human serum was completely bound to autoantibodies making it undetectable in a standard capture ELISA ([Fig. 3B](#)). Evaluation of M-CSF with and without acidification–ultrafiltration revealed that M-CSF was present in the serum in a form not bound by autoantibody ([Fig. 3C](#)). Thus M-CSF, a cytokine normally abundant in serum is not associated with anti-cytokine antibodies [10], while G-CSF, which is normally poorly/not detectable [11] is present in only in the form of complexes.

4. Discussion

Our results show that the detection of anti-cytokine autoantibodies in serum is hampered by binding to their respective




Fig. 1. Removal of the cytokine ligand improves detection of anti-cytokine autoantibodies in the serum of disease-free, healthy individuals. (A) Immunoblotting to detect anti-cytokine autoantibodies in IVIG. (B) Immunoblotting to detect anti-cytokine autoantibodies in serum from healthy human individuals. (C) Representative photographs of PVDF membrane showing protein staining with CBB (CBB) or immunoblotting (IB) to detect autoantibodies for specific cytokines. (*) Human serum albumin coexisted with rIL-6. (†) Dimeric cytokine (IL-8, IL-10). (‡) Thrombin-cleaved N-terminal OPN (nOPN) coexisted with full length OPN (fOPN).

cytokine target. “Acidification-ultrafiltration procedure” enabled us to detect cytokine-autoantibody complexes which

Table 1
Prevalence of anti-cytokine autoantibodies in disease-free, healthy individuals

Cytokine	Isoelectric point (pI)	Acidification-ultrafiltration no. positive (percent)	
		Not employed	Employed
IL-2	6.60–6.83	0 (0)	15 (100)
IL-3	5.80–7.60	0 (0)	0 (0)
IL-4	9.42–9.90	0 (0)	14 (93.3)
IL-6	6.18–7.30	0 (0)	1 (6.7)
IL-8	5.00–7.85	0 (0)	15 (100)
IL-10	9.85–9.90	0 (0)	11 (73.3)
TNF-α	7.16–9.70	0 (0)	15 (100)
OPN	4.00	0 (0)	0 (0)
VEGF	6.40–7.30	0 (0)	15 (100)
G-CSF	5.50–6.10	0 (0)	15 (100)
M-CSF	4.68–4.70	0 (0)	0 (0)
IFN-γ	10.20	0 (0)	1 (6.7)

might have been always overlooked. The method made it possible to evaluate more accurate frequency of anti-cytokine autoantibodies, and which resulted in the discovery that anti-cytokine autoantibodies are ubiquitous in healthy individuals. These observations have important implications for investigations regarding the pathological and potential physiological roles of such autoantibodies in health and disease. Anti-cytokine antibodies are present in autoimmune diseases, including rheumatoid arthritis [1,2], acute respiratory distress syndrome (ARDS) [12], Felty’s syndrome [3], and pulmonary alveolar proteinosis [4–6]. Importantly, circulating immune complexes comprised of autoantibody and cytokine ligands have been demonstrated in some, e.g., IL-8 in ARDS [12], and GM-CSF in pulmonary alveolar proteinosis [6]. Multiple reports have suggested that anti-cytokine autoantibodies are infrequently present in healthy subjects [13–15]. However, the prevalence of anti-cytokine autoantibodies in healthy individuals has been underestimated in previous reports. Surprisingly, such autoantibodies were ubiquitous in healthy individuals, a




Fig. 2. Binding specificity of serum anti-VEGF autoantibodies isolated from IVIG. (A) Relative binding capacity of anti-VEGF autoantibody to multiple other cytokines. Each values were compared with that to rhVEGF and expressed as percent binding. (B) Binding inhibition of anti-VEGF autoantibody to recombinant VEGF with soluble cytokines. Relative binding capacity was expressed as percentage to control. (C) Saturation binding plot of VEGF to anti-VEGF autoantibody. The average affinity (K_{av}) was calculated on the basis of Michaelis–Menten’s theory.




Fig. 3. Quantification of cytokines free in the serum and in the cytokine-antibody complexes. (A) G-CSF levels recovered with acidification-ultrafiltration step with various acidic conditions were quantified by ELISA. (B, C) Levels of cytokines in the immune complex (Ab-bound) or in the serum (Free). Each dot represents individual samples.

finding that will be useful to confirm in larger groups of individuals comprising a broad range of ages, genders, regions, and cultures.

The range of autoantibodies to different cytokines varied among healthy individuals. Autoantibodies against some cytokines were present in all, while some were variably detected

and some were not detected in any individuals. It is tempting to speculate about the potential mechanistic significance of such differences in the presence of autoantibodies directed against specific cytokines. It is possible that cytokines that are normally abundant in serum (M-CSF, OPN) [10,16] may have led to clonal elimination of lymphocytes directed against these cytokines by thymic programming during development. As a corollary, the presence of some anti-cytokine autoantibodies might be explained by their lack of expression during development and failure to eliminate the relevant clones. The variable presence of some autoantibodies may reflect differences in cytokine production among individuals, for example, due to differences in immunological background or arising from differences in prior microbial infection or allergen challenge. Alternatively, a biophysical parameter of the cytokine, e.g., affinity or property of its interaction with its anti-cytokine autoantibody, e.g., conditions of optimal dissociation, may be responsible for the differences. Reports have previously proposed that anti-cytokine autoantibodies may limit the 'down stream' movement of cytokines beyond the site of action, thus preventing unwanted actions elsewhere [2,6]. Although future studies will be required to determine, the consistent presence of autoantibodies against G-CSF, IL-2, IL-8, TNF- α , and VEGF in healthy individuals suggests their potential physiological role in the regulation of biological activities of cytokines. We assume that autoantibodies have three potential roles. Firstly, they neutralize cytokines to regulate their bioactivity [6]. Secondly, the cytokine-autoantibody complexes act as reservoir for cytokines which elongates the half-life time [17]. Lastly, per se, cytokine-autoantibody complexes themselves show bioactivities via Fc γ receptor [12,18].

In conclusion, we found that most anti-cytokines autoantibodies are forming cytokine-autoantibody complexes, and are detected ubiquitously in the sera from normal subjects. We believe that our discovery will contribute to better understanding of the autoantibodies as an important regulatory factor in the healthy subjects.

Acknowledgments: We thank following researchers and institutes for providing reagents; Dr. Y. Yokosaki (Hiroshima University, Japan) for fOPN and nOPN, Kirin Brewery Co., Ltd. (Tokyo, Japan) for human IL-3 and G-CSF, Hayashibara Biochemical laboratories, Inc. (Osaka, Japan) for IFN- γ and Mitsubishi Pharma Corporation (Tokyo, Japan) for Venoglobulin[®]-IH (IVIg). We also thank Dr. Seymour JF (Peter MacCallum Cancer Center, Australia) for his critical review of the manuscript. This work was supported by grants from the Ministry of Health, Labor, and Welfare of Japan (Grant H14-trans-014) (K.N.) and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (K.N.).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.febslet.2007.04.029](https://doi.org/10.1016/j.febslet.2007.04.029).

References

- [1] Graudal, N.A., Svenson, M., Tarp, U., Garred, P., Jurik, A.G. and Bendtzen, K. (2002) Autoantibodies against interleukin alpha in rheumatoid arthritis: association with long term radiographic outcome. *Ann. Rheum. Dis.* 61, 598–602.
- [2] Sjöwall, C., Ernerudh, J., Bengtsson, A.A., Sturfelt, G. and Skogh, T. (2004) Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus. *J. Autoimmun.* 22, 315–323.
- [3] Hellmich, B., Csernok, E., Schatz, H., Gross, W.L. and Schnabel, A. (2002) Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. *Arthritis Rheum.* 46, 2384–2391.
- [4] Kitamura, T., Tanaka, N., Watanabe, J., Uchida, Kanegasaki, S., Yamada, Y. and Nakata, K. (1999) Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. *J. Exp. Med.* 190, 875–880.
- [5] Kitamura, T. et al. (2000) Serological diagnosis of idiopathic pulmonary alveolar proteinosis. *Am. J. Respir. Crit. Care Med.* 162, 658–662.
- [6] Uchida, K. et al. (2004) High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. *Blood* 103, 1089–1098.
- [7] Svenson, M., Hansen, M.B. and Bendtzen, K. (1993) Binding of cytokines to pharmaceutically prepared human immunoglobulin. *J. Clin. Invest.* 92, 2533–2539.
- [8] Svenson, M., Hansen, M.B., Ross, C., Diamant, M., Rieneck, K., Nielsen, H. and Bendtzen, K. (1998) Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. *Blood* 91, 2054–2061.
- [9] Ragnhammar, P., Friesen, H.J., Frodin, J.E., Lefvert, A.K., Hassan, M., Osterborg, A. and Mellstedt, H. (1994) Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (*Escherichia coli*-derived) antibodies and clinical effects in nonimmunocompromised patients. *Blood* 84, 4078–4087.
- [10] Janowska-Wieczorek, A., Belch, A.R., Jacobs, A., Bowen, D., Padua, R.A., Paietta, E. and Stanley, E.R. (1991) Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. *Blood* 77, 1796–1803.
- [11] Watari, K., Asano, S., Shirafuji, N., Kodo, H., Ozawa, K., Takaku, F. and Kamachi, S. (1989) Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. *Blood* 73, 117–122.
- [12] Kurdowska, A., Noble, J.M., Steinberg, K.P., Ruzinski, J.T., Hudson, L.D. and Martin, T.R. (2001) Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. *Am. J. Respir. Crit. Care Med.* 163, 463–468.
- [13] Galle, P., Svenson, M., Bendtzen, K. and Hansen, M.B. (2004) High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. *Eur. J. Immunol.* 34, 3267–3275.
- [14] Hansen, M.B., Svenson, M., Abell, K., Varming, K., Nielsen, H.P., Bertelsen, A. and Bendtzen, K. (1994) Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans. *Eur. J. Clin. Invest.* 24, 212–218.
- [15] Revoltella, R.P., Laricchia-Robbio, L., Moscato, S., Genua, A. and Liberati, A.M. (1997) Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum. *Leuk. Lymphoma* 26 (Suppl. 1), 29–34.
- [16] Fedarko, N.S., Jain, A., Karadag, A., Van Eman, M.R. and Fisher, L.W. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. *Clin. Cancer Res.* 7, 4060–4066.
- [17] Courtney, L.P., Phelps, J.L. and Karavodin, L.M. (1994) An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. *Immunopharmacology* 28, 223–232.
- [18] Boyman, O., Kovar, M., Rubinstein, M., Surh, C.D. and Sprent, J. (2006) Selective stimulation of T cell subsets with antibody-cytokine immune complexes. *Science*.